

# Biochemistry – HLS

Done By

Hani Titi

Corrected By

Samah Freihat



# Metabolism in erythrocytes

Prof. Mamoun Ahram Hematopoietic-lymphatic system




- This lecture
- Lippincott's Biochemistry, 7<sup>th</sup> edition
- The Medical Biochemistry Page  
(<https://themedicalbiochemistrypage.org/>)

# Carbohydrate metabolism in RBC



- Glycolysis produces :
  - 2,3-bisphosphoglycerate (2,3-BPG)
  - NADH
- Pentose phosphate pathway
  - NADPH





# **2,3-bisphosphoglycerate (2,3-BPG)**




# Generation of 2,3-BPG



- 2,3-bisphosphoglycerate (2,3-BPG) is derived from the glycolytic intermediate 1,3-bisphosphoglycerate. (2,3-BPG is a by-product and an isomer)
- It can re-enter the glycolytic pathway.

The erythrocyte loses the ability to gain 2 moles of ATP.



- ❖ **2,3-BPG binds to the center of Hb; stabilizing T-state and reducing affinity towards O<sub>2</sub>**



# Effect of 2,3-BPG on Hb



- ❖ 2,3-BPG occupies the center of deoxygenated Hb stabilizing it in the T structure.
- ❖ When 2,3-BPG is not available (not bound), Hb can be easily converted to the R-structure.



- **2,3-BPG interacts with several amino acids considering its negative charge (binds positively charged molecules like Histidine and Lysine via electrostatic interactions) and reduces binding of oxygen to hemoglobin.**
- **Increasing the concentration of 2,3-BPG shifts the curve to the right meaning that affinity is reduced.**








# 2,3-BPG and HbF

- BPG interacts with several groups including a lysine, His143, His2, and N-terminal ends of the  $\beta$  chain.
- Fetal hemoglobin (HbF) binds 2,3-BPG much less strongly than HbA.
- HbF binds serine instead of binding His143, this weakens interactions between 2,3-BPG and Hb and increasing the affinity of binding O<sub>2</sub>**

**His143 is replaced by a serine in the  $\gamma$  chain.**

**Re-record**







# Glycolysis



# Main purpose




- Glycolysis provides
  - NADH for **reduction** of methemoglobin (hemoglobin with oxidized  $\text{Fe}^{3+}$  in heme)
  - ATP for
    - Modifying sugars and proteins
    - Maintaining membrane asymmetry
    - Functions of membrane ion pumps
    - Regulating cytoskeletal proteins
      - Maintenance of the discocyte shape, which is critical for the optimal viability and functional capacity.





❖ In glycolytic pathway, glucose is ultimately converted into pyruvate .

❖ The last reaction is catalyzed by Pyruvate Kinase which produces ATP by phosphorylating ADP.





# Pyruvate kinase isozymes and regulation




Check the next slide for the difference between isoenzymes and isoforms

- There are two isoenzyme genes of PK and each produces two isoforms: (**different transcription start sites**).
  - PK**L** (liver) and PK**R** (erythrocytes) are produced from PKLR gene.
  - PKM1 (muscle and brain) and PKM2 (fetal and most tissues) produced from PKM gene.
- Fetal PK isozyme (**PKM2**) has much greater activity than the adult isozymes. (**Reduced amounts of glycolytic intermediates**)

Fetal erythrocytes have lower concentrations of glycolytic intermediates including 1,3BPG (and 2,3BPG).

**Remember: lower 2,3BPG means higher Hb in R-state; higher affinity towards O<sub>2</sub>**



**Isozymes:** different enzymes produced by different genes with different catalytic activity and regulation, also they differ in the tissue where they function .


**Isoformes :** different enzymes but they are produced from the same gene (same RNA) by splicing from another region on the RNA

(Like if u have gene 1 which gives us RNA , this RNA have many sites on it , if u cut site 1 u will get enzyme1 and if u cut site 2 u will get enzyme 2 , these two enzymes are called isoforms , same gene)

# Regulation of PK



- The PKLR is allosterically regulated:
  - inhibited by ATP, acetyl-CoA, alanine, and long-chain fatty acids and by phosphorylation by protein kinase A (**high glucagon levels**) .
  - activated by F1,6-BP.
- The liver enzyme (PKL) is also controlled at the level of synthesis.
  - Increased carbohydrate ingestion induces the synthesis of PK.






# PK deficiency



- Genetic diseases of adult erythrocyte PK where the kinase is virtually inactive.
- The erythrocytes have a greatly reduced capacity to make ATP, which causes hereditary hemolytic anemia **(caused by single point mutation)**.
- The severity of the disease depends on the degree of enzyme deficiency (5-35%) and ability to produce 2,3-BPG.
- Liver is not affected since expression is stimulated.









# The pentose phosphate pathway

# Two phases of pentose phosphate pathway




- The oxidative generation of NADPH
  - NADPH is generated when glucose 6-phosphate is oxidized to ribulose 5-phosphate.
- The nonoxidative interconversion of sugars



# The first step




- The oxidative phase of the pentose phosphate pathway starts with the dehydrogenation of glucose 6-phosphate by glucose 6-phosphate dehydrogenase.



- G6PD is highly specific for NADP<sup>+</sup>, relative to NAD<sup>+</sup>
- The reaction is irreversible, is the rate limiting reaction. (**highly regulated**)
- High levels of NADP<sup>+</sup> stimulate the reaction .




# Oxidative stress and glutathione



- Oxidative stress within cells is controlled primarily by the action of glutathione (GSH).
- GSH reduces peroxides via glutathione peroxidase.
- GSH is regenerated via NADPH-dependent glutathione reductase.
- The PPP in erythrocytes is the only pathway to produce NADPH.

PPP consumes almost 10% of glucose by erythrocytes.





# Low GSH levels



- The inability to maintain reduced glutathione in RBCs leads to increased accumulation of peroxides, predominantly  $H_2O_2$ , resulting in
  - Weakening of the cell membrane and concomitant hemolysis (**hydrogen peroxide oxidizes fatty acids**)  
increasing rates of oxidation of hemoglobin to methemoglobin and other proteins including membrane proteins, insolubilizing them forming Heinz bodies, weakening the cell membrane.





# **Glucose-6-phosphate dehydrogenase deficiency**


# G6PD deficiency



- Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a group of heterogeneous disease with significantly reduced activity.
  - **Hemolytic anemia (severe)**
    - particularly after the administration of drugs, during infections and in the neonatal period (jaundice)
- Deficiency of G6PD is most prevalent in individuals of African, Mediterranean, and Oriental ethnic origins.
- It is the most common enzyme deficiency worldwide.
- G6PD gene is located on the X chromosome.
  - **Inheritance of G6PD deficiency is sex-linked.**







**Frequency of G6PD deficient males %**

- |         |            |
|---------|------------|
| < 0.5   | 7.0–9.9    |
| 0.5–2.9 | 10.0–14.9  |
| 3.0–6.9 | 15.0–126.0 |

**Polymorphic G6PD variants**

- |           |         |               |               |
|-----------|---------|---------------|---------------|
| A- (202A) | Chatham | Mediterranean | Taipei        |
| A- (968C) | Coimbra | Mahidol       | Union         |
| Aures     | Cosenza | Santamaria    | Viangchan     |
| Canton    | Kaiping | Seattle       | Local variant |

# G6PD mutations



- Several hundred G6PD genetic variants have been identified, but most have no clinical symptom.
- Almost all G6PD deficiency variants are caused by single point mutations in the gene.
  - Mainly these mutations alter the kinetic properties, stability, or binding affinity to NADP<sup>+</sup> or G6P.
- No large deletions or frameshift mutations. Why?

# The four classes of G6PD deficiency



- G6PD B (Normal)

- Abnormal G6PDs

- Class I are most severe and rare (**results in chronic hemolytic anemia**)

- Class IV: no clinical symptoms

- G6PD A- (group III or class III)

- Among persons of African descent
- It is caused by a single amino acid substitution of Asn to Asp that decreases enzyme stability, but 5-15% of normal activity.

- The disease is moderate.

- **G6PD Mediterranean (group II or class II)**

- Severe

- The enzyme has normal stability, but negligible activity.

Class	Clinical symptoms	Residual enzyme activity
I	Very severe (chronic hemolytic anemia)	<2%
II	Severe (episodic hemolytic anemia)	<10%
III	Moderate	10%-60%
IV	None	>60%



# Class II vs. class III



As RBCs age the activity of G6PD is reduced


## G6PD A- (class III):

Moderate, young RBCs contain enzymatic activity. Unstable enzyme, but kinetically normal

Enzymatic activity is still high

## G6PD Mediterranean (II)

Enzyme with normal stability but low activity (severe). Affect all RBCs (both young and old)



# Inducers of G6PD deficiency symptoms



- Oxidant drugs
  - Antibiotics, anti-malarial, and anti-pyretics (not acetaminophen)
- Fava beans (favism)
  - Substances capable of destroying red cell GSH have been isolated from fava beans (fool)
  - Favism is most common in persons with G6PD class II variants, but rarely can occur in patients with the G6PD A- variant.
  - Fava beans are presumed to cause oxidative damage by an unknown component
- Infection
  - The most common inducer due to production of free radicals.



# Connection to malaria

- Several G6PD deficiencies are associated with resistance to the malarial parasite, *Plasmodium falciparum*, among individuals of Mediterranean and African descent.
- The basis for this resistance is the weakening of the red cell membrane (the erythrocyte is the host cell for the parasite) such that it cannot sustain the parasitic life cycle long enough for productive growth.

